These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 22367645)

  • 1. Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01).
    Azim HA; Metzger-Filho O; de Azambuja E; Loibl S; Focant F; Gresko E; Arfi M; Piccart-Gebhart M
    Breast Cancer Res Treat; 2012 May; 133(1):387-91. PubMed ID: 22367645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01).
    Pestalozzi BC; Holmes E; de Azambuja E; Metzger-Filho O; Hogge L; Scullion M; Láng I; Wardley A; Lichinitser M; Sanchez RI; Müller V; Dodwell D; Gelber RD; Piccart-Gebhart MJ; Cameron D
    Lancet Oncol; 2013 Mar; 14(3):244-8. PubMed ID: 23414588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
    Baselga J; Perez EA; Pienkowski T; Bell R
    Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial.
    Procter M; Suter TM; de Azambuja E; Dafni U; van Dooren V; Muehlbauer S; Climent MA; Rechberger E; Liu WT; Toi M; Coombes RC; Dodwell D; Pagani O; Madrid J; Hall M; Chen SC; Focan C; Muschol M; van Veldhuisen DJ; Piccart-Gebhart MJ
    J Clin Oncol; 2010 Jul; 28(21):3422-8. PubMed ID: 20530280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?
    Constantinidou A; Smith I
    Breast; 2011 Oct; 20 Suppl 3():S158-61. PubMed ID: 22015286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data.
    Shiroiwa T; Fukuda T; Shimozuma K; Ohashi Y; Tsutani K
    Breast Cancer Res Treat; 2008 Jun; 109(3):559-66. PubMed ID: 17661170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal.
    Ward S; Pilgrim H; Hind D
    Health Technol Assess; 2009 Jun; 13 Suppl 1():1-6. PubMed ID: 19567207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical practice-changing trials: the HERA study paradigm.
    Zardavas D; Ades F; de Azambuja E
    Expert Rev Anticancer Ther; 2013 Nov; 13(11):1249-56. PubMed ID: 24138446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.
    Suter TM; Procter M; van Veldhuisen DJ; Muscholl M; Bergh J; Carlomagno C; Perren T; Passalacqua R; Bighin C; Klijn JG; Ageev FT; Hitre E; Groetz J; Iwata H; Knap M; Gnant M; Muehlbauer S; Spence A; Gelber RD; Piccart-Gebhart MJ
    J Clin Oncol; 2007 Sep; 25(25):3859-65. PubMed ID: 17646669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is there a qualitative interaction between adjuvant trastuzumab and size of the primary tumor in breast cancer?
    Vesely P; Melichar B
    Neoplasma; 2008; 55(5):375-80. PubMed ID: 18665746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ectopic pregnancy in a breast cancer patient receiving trastuzumab.
    Berveiller P; Mir O; Sauvanet E; Antoine EC; Goldwasser F
    Reprod Toxicol; 2008 Feb; 25(2):286-8. PubMed ID: 18201867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Favorable pregnancy outcome following Trastuzumab (Herceptin) use during pregnancy--Case report and updated literature review.
    Shrim A; Garcia-Bournissen F; Maxwell C; Farine D; Koren G
    Reprod Toxicol; 2007 Jun; 23(4):611-3. PubMed ID: 17399946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer.
    Chen J; Long JB; Hurria A; Owusu C; Steingart RM; Gross CP
    J Am Coll Cardiol; 2012 Dec; 60(24):2504-12. PubMed ID: 23158536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant trastuzumab therapy for HER2-positive breast cancer.
    Jahanzeb M
    Clin Breast Cancer; 2008 Aug; 8(4):324-33. PubMed ID: 18757259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study].
    Mallmann P
    Internist (Berl); 2006 Nov; 47(11):1183-5. PubMed ID: 17048017
    [No Abstract]   [Full Text] [Related]  

  • 16. When an interim analysis of randomized trial changes the practice in oncology: The lesson of adjuvant trastuzumab and the HERA trial.
    De Rossi C; Brunello A; Jirillo G; Jirillo A
    Immunopharmacol Immunotoxicol; 2009; 31(1):1-4. PubMed ID: 19238693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementation of trastuzumab in conjunction with adjuvant chemotherapy in the treatment of non-metastatic breast cancer in the Netherlands.
    de Munck L; Schaapveld M; Siesling S; Wesseling J; Voogd AC; Tjan-Heijnen VC; Otter R; Willemse PH
    Breast Cancer Res Treat; 2011 Aug; 129(1):229-33. PubMed ID: 21431871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perinatal outcomes of a pregnancy complicated by cancer, including neonatal follow-up after in utero exposure to chemotherapy: results of an international registry.
    Cardonick E; Usmani A; Ghaffar S
    Am J Clin Oncol; 2010 Jun; 33(3):221-8. PubMed ID: 19745695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Update: adjuvant trastuzumab in HER2 positive breast cancer].
    Tahover E; Sonnenblick A; Peretz T; Katz D
    Harefuah; 2012 Jan; 151(1):37-42, 61. PubMed ID: 22670500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Medical treatment of primary breast cancer: new targeted biological treatments].
    Andersson M; Nielsen DL
    Ugeskr Laeger; 2007 Sep; 169(37):3082-4. PubMed ID: 17877953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.